Pages that link to "Q61643925"

The following pages link to Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes (Q61643925):

Displaying 39 items.

• In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats (Q28363020) (← links)
• In vitro metabolism of citalopram by monoamine oxidase B in human blood (Q32066064) (← links)
• Omeprazole preferentially inhibits the metabolism of ( )-(S)-citalopram in healthy volunteers (Q34019331) (← links)
• Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations (Q34065310) (← links)
• Escitalopram : a review of its use in the management of major depressive and anxiety disorders (Q34186994) (← links)
• CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages (Q34352560) (← links)
• Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram (Q34353067) (← links)
• Role of drug metabolism in drug discovery and development (Q34386829) (← links)
• Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area (Q34879739) (← links)
• CYP2C19 variation and citalopram response (Q34954026) (← links)
• Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review (Q35054424) (← links)
• Antidepressant Drugs in the Elderly — Rôle of the Cytochrome P450 2D6 (Q35106246) (← links)
• Toxicological interactions involving psychiatric drugs and alcohol: an update (Q35114132) (← links)
• Great expectations in stereochemistry: focus on antidepressants. (Q35766749) (← links)
• Exploring the role of drug-metabolising enzymes in antidepressant side effects (Q35780023) (← links)
• PharmGKB summary: citalopram pharmacokinetics pathway (Q35952370) (← links)
• Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family (Q36441503) (← links)
• The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants (Q36510896) (← links)
• Escitalopram: a review of its use in the management of anxiety disorders (Q36585863) (← links)
• Applicability of the Rayleigh equation for enantioselective metabolism of chiral xenobiotics by microsomes, hepatocytes and in-vivo retention in rabbit tissues. (Q36735906) (← links)
• Predicting CYP2C19 catalytic parameters for enantioselective oxidations using artificial neural networks and a chirality code (Q36906273) (← links)
• Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. (Q37611786) (← links)
• Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy (Q37742091) (← links)
• The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes (Q38283667) (← links)
• Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine (Q41612679) (← links)
• Stereoselective single-dose kinetics of citalopram and its metabolites in rats (Q42164280) (← links)
• The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats (Q42167000) (← links)
• Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. (Q43244977) (← links)
• On-line extraction using an alkyl-diol silica precolumn for racemic citalopram and its metabolites in plasma. Results compared with solid-phase extraction methodology. (Q43595956) (← links)
• In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations (Q43882785) (← links)
• Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study (Q43990916) (← links)
• CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis (Q44784776) (← links)
• P450 Pharmacogenetics in Indigenous North American Populations (Q47546933) (← links)
• An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents (Q48416128) (← links)
• Cytochrome p450‐dependent disposition of the enantiomers of citalopram and its metabolites: In vivo studies in Sprague‐Dawley and Dark Agouti rats (Q51541896) (← links)
• Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients (Q51901597) (← links)
• In vitrometabolism of α7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for itsN-oxide metabolite (Q57099418) (← links)
• Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: Application to pharmacokinetics (Q62539051) (← links)
• Production of metabolites of the anti-cancer drug noscapine using a P450BM3 mutant library (Q90088365) (← links)